Technology | Heart Failure | July 30, 2019

Procyrion Receives FDA Breakthrough Device Designation for Aortix System

Resting the heart while perfusing the kidneys, Aortix aims to treat heart failure symptoms by disrupting the cardiorenal syndrome cycle

Procyrion Receives FDA Breakthrough Device Designation for Aortix System

July 30, 2019 – Procyrion Inc. secured Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for its Aortix System. Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) with worsening renal function.

Breakthrough Designation is granted to certain medical devices and device-led combination products that provide a more effective treatment of life-threatening or irreversibly debilitating diseases. It enables manufacturers to provide patients and healthcare providers with timely access to medical devices by expediting their development, assessment and review. Benefits of this designation include frequent interactions and feedback from FDA during the premarket review phase. Through this program, Procyrion can expect prioritized review of its FDA submissions for the Aortix System. In addition, the Centers for Medicare and Medicaid Services (CMS) recently proposed a new rule1 that would provide coverage and increase payments for medical devices designated by the FDA as breakthrough devices, so Medicare beneficiaries do not have to wait for access to the latest innovations. 

“With Aortix, we have a device innovation that truly warrants breakthrough designation for the treatment of ADHF patients with worsening renal function, a particularly challenging group of patients for whom outcomes are generally poor and treatment options limited,” commented Keith Aaronson, M.D., MS, Pitt Collegiate Professor of Cardiovascular Medicine and medical director of the Center for Circulatory Support at the University of Michigan.

Heart failure (HF) is common, affecting more than 6 million adults and resulting in more than 1 million annual hospitalizations in the United States alone.[2]  HF costs the nation an estimated $30.7 billion each year.[3] HF is a chronic, progressive condition, marked by episodes of acute decompensation typically requiring hospitalization for stabilization and improvement in symptoms. Unfortunately, outcomes after hospitalization for decompensated heart failure are poor. The one-year mortality rate after a heart failure hospitalization has remained high at 20-30 percent,[4] and there is additive risk with each subsequent hospitalization.[5,6] In addition, at least moderate renal dysfunction (Stage III) is present in up to 64 percent of ADHF admissions,[7] and it is estimated that more than 325,000 admissions per year in the U.S. are for patients with ADHF who also have worsening renal function.[8] These patients represent a particularly high-risk population, as they are frequently non-responders to available medical therapy and have poor outcomes. 

The Aortix System is a percutaneous circulatory support device for the treatment of heart failure. The initial version of the Aortix device provides up to seven days of circulatory support for chronic heart failure patients who have been hospitalized for ADHF, have worsening renal function, and are unresponsive to medical management. As demonstrated in animal studies[9] and a six-patient First-in-Human study,[10] Aortix benefits both the heart and the kidneys based on its unique design and placement in the descending thoracic aorta. Aortix can disrupt the harmful cardiorenal cycle in two ways: above the pump, it rests the heart by reducing aortic root pressure (afterload) resulting in increased cardiac output and decreased cardiac work; downstream, it provides increased blood flow to the kidneys resulting in increased urine output and a reduction in fluid overload. The device is placed via a minimally invasive catheter-based procedure that takes less than 10 minutes.

For more information: www.procyrion.com

Related Aortix Content

VIDEO: Advances in Interventional Heart Failure Hemodynamic Support 

Aortix Heart Failure Pump Chosen for TCT “Shark Tank” Competition

Reducing Economic Burden of Cardiorenal Syndrome With The Aortix Pump

 

References:

1. https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-08330.pdf

2. Benjamin, E. J. et al. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation CIR.0000000000000485 (2017). doi:10.1161/cir.0000000000000485

3. Heidenreich, P. A. et al. Forecasting the Future of Cardiovascular Disease in the United States. Circulation 123, 933–944 (2011).

4. Chen, J., Normand, S.-L. T., Wang, Y. & Krumholz, H. M. National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008. JAMA 306, 1669–1678 (2011).

5. Solomon, S. D. et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116, 1482–7 (2007).

6. Setoguchi, S., Stevenson, L. & Schneeweiss, S. Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal 154, 260–266 (2007).

7. Heywood, J. et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. Journal of cardiac failure 13, 422–30 (2007).

8. Adams, K. F. et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149, 209–216 (2005).

9. Shabari, F. et al. Improved Hemodynamics With a Novel Miniaturized Intra-aortic Axial Flow Pump in a Porcine Model of Acute Left Ventricular Dysfunction. ASAIO Journal 59, 240 (2013).

10. Vora, A. N. et al. First‐in‐human experience with Aortix intraaortic pump. Catheter Cardio Inte (2018). doi:10.1002/ccd.27857

Related Content

NIVAHF is an investigational device designed to monitor the venous waveform, a novel physiologic signal, in heart failure patients

NIVAHF is an investigational device designed to monitor the venous waveform, a novel physiologic signal, in heart failure patients.

News | Heart Failure | June 15, 2021
June 15, 2021 — VoluMetrix, a Nashville-based biotech startup dedicated to creating a new wave of solutions for vital
The Aortix intra-aortic axial flow pump offers hemodynamic support to relieve some of the heart’s workload, allowing the heart to recover while more effectively pushing blood flow to the kidneys.

The Aortix intra-aortic axial flow pump offers hemodynamic support to relieve some of the heart’s workload, allowing the heart to recover while more effectively pushing blood flow to the kidneys.

News | Heart Failure | June 07, 2021
June 7, 2021 – Cardiologists at Hen...
RAFT-AF study showed type of heart failure may influence treatment strategies for heart rate management vs. arrhythmia control in in patients with heart  heart and atrial fibrillation. #ACC21 #ACC2021

RAFT-AF study showed the type of heart failure may influence treatment strategies for heart rate management vs. arrhythmia control in in patients with heart heart and atrial fibrillation. Getty Images

News | Heart Failure | May 19, 2021
May 19, 2021 — Among patients with both ...
The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients. #ACC21 #ACC2021 #GALACTICHF

The results of the GALACTIC-HF trial shows omecamtiv mecarbil offers benefits to severe heart failure patients.

News | Heart Failure | May 18, 2021
May 18, 2021 — The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a gre
The combination heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin converting enzyme (ACE) inhibitor. #ACC21 #ACC2021

The combination heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin converting enzyme (ACE) inhibitor.

News | Heart Failure | May 15, 2021
May 15, 2021 — The combination heart failure drug sacubitril/valsartan (Entresto) did not significantly reduce the ra
Patients hospitalized with COVID-19 may be at risk of developing heart failure even if they do not have a previous history of heart disease or cardiovascular risk factors, a new Mount Sinai study shows. 

Getty Images

News | Heart Failure | May 11, 2021
May 11, 2021 — Patients hospitalized with COVID-1...
Racism and heart disease. This study looks at heart failure patients and the impact of socioeconomic disparities associate with epigenetics. The study looks to overcome preconcieved ideas about race in cardiac studies by looking at underlaying causes for the disease. Image courtesy of the American Journal of Physiology

Image courtesy of the American Journal of Physiology.

News | Heart Failure | April 26, 2021
April 26, 2021 – Cardiovascular diseases are the leading cause of death in the United States.
PA pressure-guided heart failure management is fast becoming the standard of care in NYHA Class III patients. The Cordella Pulmonary Artery Pressure Sensor enables clinicians to remotely monitor and proactively adjust therapy and medications remotely without the need for office visits.

PA pressure-guided heart failure management is fast becoming the standard of care in NYHA Class III patients. The Cordella Pulmonary Artery Pressure Sensor enables clinicians to remotely monitor and proactively adjust therapy and medications remotely without the need for office visits.

News | Heart Failure | March 24, 2021
March 24, 2021 — Endotronix Inc., a digital health and medical technology company working on advancements in treating
Impulse Dynamics Optimizer Smart device is an implantable device that helps optimize cardiac pumping action in heart failure patients.

Impulse Dynamics Optimizer Smart device is an implantable device that helps optimize cardiac pumping action in heart failure patients.

News | Heart Failure | March 03, 2021
March 3, 2021 — Impulse Dynamics recently announced that...
LVAD patient Richard Huggins with the external control and power unit for his new EvaHeart2 left ventricular assist device at Penn State Health's Hershey Medical Center. 

LVAD patient Richard Huggins with the external control and power unit for his new EvaHeart2 left ventricular assist device at Penn State Health's Hershey Medical Center. 

News | Heart Failure | March 02, 2021
March 2, 2021 — P...